Last Price$205.7(1.0%)
Market Cap$151.3B
(0.1%)
Peers median - 1.5%
22.2%
Peers median - 16.4%
32.3%
Peers median - 39.1%
5.9%
Peers median - 11.7%
Competing with DHR
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$151.3B | 6.1 | $167.0 18.8% overvalued | (19.4%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$201.0B | 6.5 | $602.4 15.0% undervalued | (9.7%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 8.3% | 63.1% | |
$36.5B | 7.4 | $103.7 17.9% overvalued | (11.0%) | $6,533.0M | $1,409.0M | (3.0%) | 21.6% | 65.9% | 14.7% | 55.8% | |
$36.1B | 7.2 | $219.3 49.8% overvalued | (23.5%) | $3,897.5M | $798.1M | 6.5% | 20.5% | 61.1% | 49.4% | 6.3% | |
$33.7B | 6.1 | $301.3 63.0% undervalued | (26.5%) | $15.4B | $2,114.0M | 2.5% | 13.7% | 31.4% | 8.8% | 21.7% | |
$27.1B | 7.0 | $869.6 31.5% overvalued | (1.4%) | $3,872.4M | $864.4M | 2.2% | 22.3% | 59.1% | 49.8% | (1,587.1%) | |
$22.2B | 6.5 | $236.1 36.5% overvalued | 7.2% | $2,958.4M | $619.6M | 0.1% | 20.9% | 58.2% | 19.4% | 0.0% | |
$21.2B | 6.1 | $621.0 144.4% undervalued | 17.1% | $13.0B | $1,095.9M | 0.8% | 8.4% | 26.9% | 6.0% | 24.1% | |
$19.6B | 6.0 | $369.8 109.0% undervalued | 44.2% | $9,872.0M | $909.0M | 6.7% | 9.2% | 32.4% | 8.8% | 102.2% | |
$18.5B | 6.0 | $70.9 50.4% overvalued | 58.6% | $1,532.0M | ($33.2M) | 54.9% | (2.2%) | 57.7% | (44.9%) | 54.2% | |
$13.9B | 6.2 | $147.2 74.8% undervalued | (37.1%) | $4,372.0M | $696.0M | (2.9%) | 15.9% | 65.4% | 34.6% | 93.8% |
Compare DHR Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Danaher CorporationDHR
6.9x
(0.1%)
(17.9%)
16.3%
Median Peer Set
5.6x
(1.7%)
(2.0%)
11.6%
Agilent Technologies, Inc.A
5.9x
(4.7%)
5.0%
19.8%
Quest Diagnostics IncorporatedDGX
2.6x
(6.4%)
(6.5%)
9.2%
IDEXX Laboratories, Inc.IDXX
9.2x
8.7%
25.2%
23.1%
Illumina, Inc.ILMN
3.5x
(2.9%)
4.6%
(28.0%)
IQVIA Holdings Inc.IQV
2.2x
2.8%
2.4%
8.9%
Laboratory Corporation of America HoldingsLH
N/A
(18.3%)
(65.8%)
3.4%
Mettler-Toledo International Inc.MTD
7.5x
2.2%
12.7%
22.3%
Natera, Inc.NTRA
11.8x
32.0%
(32.1%)
(40.2%)
Thermo Fisher Scientific Inc.TMO
5.3x
(4.6%)
(12.4%)
14.0%
Waters CorporationWAT
7.4x
(0.5%)
(7.9%)
21.7%
Compare DHR Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Danaher Corporation (DHR) revenue growth compare to peers and the industry?
Danaher Corporation (DHR) revenue growth is (0.1%), compared to the peers' median of 1.5%.
2. How does Danaher Corporation (DHR) Free Cash Flow (FCF) margin compare to peers and the industry?
Danaher Corporation (DHR) FCF margin is 22.2%, compared to the peers' median of 16.4%.
3. How does Danaher Corporation (DHR) Total Debt to Equity ratio compare to peers and the industry?
Danaher Corporation (DHR) Total Debt to Equity ratio is 32.3%, compared to the peers' median of 39.1%.
4. How does Danaher Corporation (DHR) ROIC (Return on Invested Capital) compare to peers and the industry?
Danaher Corporation (DHR) ROIC is 5.9%, compared to the peers' median of 11.7%.